Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation-Reference-Cited by-同舟云学术

Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation

Published:2011-06 Issue:25 Volume:15 Page:
ISSN:1366-5278
Container-title:Health Technology Assessment
language:en
Short-container-title:Health Technol Assess

Author:

Hislop J¹,Quayyum Z,Elders A,Fraser C,Jenkinson D,Mowatt G,Sharma P,Vale L,Petty R

Affiliation:

1. Health Services Research Unit, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK

Funder

Health Technology Assessment programme

Publisher

National Institute for Health Research

Subject

Health Policy

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology;International Journal of Clinical Oncology;2024-04-13

2. Strategic flexibility in healthcare: an exploration of real options;Journal of Economic Studies;2024-02-13

3. Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumor: A Systematic Review;Frontiers in Public Health;2022-01-10

4. Early response evaluation using 18F-FDG-PET/CT does not influence management of patients with metastatic gastrointestinal stromal tumors (GIST) treated with palliative intent;Nuklearmedizin - NuclearMedicine;2021-09-03

5. Staged surgical approach for metastatic GIST, how far should we go? Case report;International Journal of Surgery Case Reports;2021-07